Cyclo Therapeutics Announces Launch of New Website
June 15 2021 - 8:05AM
Business Wire
- Company dedicated to developing life-changing
medicines through science and innovation for patients and families
living with challenging diseases
- Pivotal Phase 3 study of Trappsol® Cyclo™ for
Niemann-Pick Disease Type C (NPC) on track to commence site
activation to begin enrollment this month
- Company advancing Alzheimer’s Disease Phase 2
asset towards investigational new drug application (IND) filing
anticipated in H2 2021
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or
the “Company”), a clinical stage biotechnology company dedicated to
developing life-changing medicines through science and innovation
for patients and families suffering from diseases, today announced
the launch of its new corporate website, cyclotherapeutics.com.
“As we drive development of our potentially life-changing
medicines, delivering treatment benefit to patients and families
suffering from NPC and Alzheimer’s Disease remain at the forefront
of our motivation and goal. Our Company is committed to remaining
active in the patient, as well as investor communities to build
awareness, much needed hope and ultimately shareholder value,”
commented N. Scott Fine, Chief Executive Officer of Cyclo
Therapeutics.
The Company’s lead product in development, Trappsol® Cyclo™ is a
proprietary formulation of hydroxypropyl beta cyclodextrin, used
intravenously (IV) and currently in development for the treatment
of NPC, a rare genetic disorder causing cholesterol accumulation in
lysosomes of cells, organ dysfunction and premature death.
Following the recent positive topline data readout from its Phase
1/2 clinical trial, which demonstrated promising safety and
efficacy results, the Company is preparing to commence its pivotal
Phase 3 study evaluating Trappsol® Cyclo™ for the treatment of NPC.
Cyclo Therapeutics remains on track to commence patient enrollment
in June 2021.
Additionally, Cyclo Therapeutics is advancing its development of
Trappsol® Cyclo™ for the treatment of Alzheimer’s Disease,
targeting the reduction of amyloid beta and tau. Following a
positive Type B interaction with the FDA, the Company received
positive feedback supporting its development strategy to submit an
IND application for a Phase 2 study of intravenous Trappsol® Cyclo™
in the treatment of early Alzheimer’s disease. The Company is on
track to file its IND for a Phase 2 study of Alzheimer’s disease in
the second half of 2021.
For more information, please visit cyclotherapeutics.com.
About Cyclo Therapeutics
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology
company dedicated to developing life-changing medicines through
science and innovation for patients and families suffering from
disease. The Company’s Trappsol® Cyclo™, an orphan drug designated
product in the United States and Europe, is the subject of three
ongoing formal clinical trials for Niemann-Pick Disease Type C, a
rare and fatal genetic disease, (www.ClinicalTrials.gov
NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company
is planning an early phase clinical trial using Trappsol® Cyclo™
intravenously in Alzheimer’s Disease based on encouraging data from
an Expanded Access program for late-onset Alzheimer’s Disease
(NCT03624842). Additional indications for the active ingredient in
Trappsol® Cyclo™ are in development. For additional information,
visit the Company’s website: www.cyclotherapeutics.com.
Safe Harbor Statement
This press release contains “forward-looking statements” about
the company’s current expectations about future results,
performance, prospects and opportunities, including, without
limitation, statements regarding the satisfaction of closing
conditions relating to the offering and the anticipated use of
proceeds from the offering. Statements that are not historical
facts, such as “anticipates,” “believes” and “expects” or similar
expressions, are forward-looking statements. These statements are
subject to a number of risks, uncertainties and other factors that
could cause actual results in future periods to differ materially
from what is expressed in, or implied by, these statements. The
factors which may influence the company’s future performance
include the company’s ability to obtain additional capital to
expand operations as planned, success in achieving regulatory
approval for clinical protocols, enrollment of adequate numbers of
patients in clinical trials, unforeseen difficulties in showing
efficacy of the company’s biopharmaceutical products, success in
attracting additional customers and profitable contracts, and
regulatory risks associated with producing pharmaceutical grade and
food products. These and other risk factors are described from time
to time in the company’s filings with the Securities and Exchange
Commission, including, but not limited to, the company’s reports on
Forms 10-K and 10-Q. Unless required by law, the company assumes no
obligation to update or revise any forward-looking statements as a
result of new information or future events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210615005172/en/
Investor Contact: JTC Team, LLC Jenene Thomas (833)
475-8247 CYTH@jtcir.com
Cyclo Therapeutics (NASDAQ:CYTH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cyclo Therapeutics (NASDAQ:CYTH)
Historical Stock Chart
From Sep 2023 to Sep 2024